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Much attention has been devoted to the consequences of the
European Medicines Agency’s departure from London because
of Brexit.1 2 Yet exclusion from other EU agencies, including
the European Monitoring Centre for Drugs and Drug Addiction
(EMCDDA), will also have serious consequences for public
health in the United Kingdom.
Founded in 1993 in Lisbon,3 the EMCDDA derives its mandate
from Regulation (EC) No 1920/20063, which involves
surveillance, establishing best practice, facilitating exchange of
knowledge and data, providing leadership on new psychoactive
substances, and assisting with policy making in countries and
in the EU. By adopting certain “red lines,” including oversight
by the Court of Justice of the European Union, the UK will
exclude itself from full membership.3 4
The EMCDDA has provided the EU and its member states with
accurate and timely intelligence and evidence based overviews
of the European drug landscape that support Europe-wide drug
policies,5 as well as facilitating exchange of best practice and
identifying priorities for research. Collaboration between the
UK and the EMCDDA has been transformative, making a major
contribution to national drug policy and the fight against
organised crime. Exclusion from its operations poses a severe
threat to both.
One priority will be to find a way to continue intelligence
sharing between the EMCDDA and the UK Focal Point on
Drugs, a part of Public Health England, through the Réseau
Européen d ́Information sur les Drogues et les Toxicomanies
(Reitox) and other European agencies.6 The intelligence
assembled by EMCDDA and Europol has been crucial to the
UK’s response to organised crime and illicit trade in drugs.7 The
UK will also need to find some way to continue to interact with
the European Union Early Warning System on novel
psychoactive substances.5 This area is changing rapidly,8 so up
to date knowledge is vital for the UK’s drug strategy. The UK
also risks exclusion from the EU Drugs Action Plan, an initiative
that will strengthen surveillance in three domains: drug markets,
drug related crime, and drug supply reduction.9 Finally, the UK
will suffer from any barriers to communicating with the
EMCDDA and Europol on strategic analysis of drug markets,3
which are founded on the EMCDDA’s datasets and Europol’s
intelligence on organised crime.10
Until the UK government can decide on a workable basis for
its long term relations with the EU, we cannot know how any
future arrangements with the EMCDDA might work. It may
accept oversight from the Court of Justice of the European
Union, at least in security, although this might not be acceptable
to some of its MPs. If accepted, this must include the EMCDDA.
Beyond that, there are concerns about the many multinational
networks operating in this area in which the UK participates as
an EU member state.
The EMCDDA has had an important, if understated, role in
supporting drug and health policy in EU member states,
including the UK. Its contributions have included developing
a strategic, situational, and holistic understanding of the complex
and fast moving European drug situation; identifying new threats
to public health and security; and establishing best practice for
effective interventions and informed policy making. The
challenges associated with Brexit arrive precisely when the UK
relies most heavily on the EMCDDA to tackle the rapidly
evolving trade in illicit substances, especially that involving
organised crime, the consequences of which are seen on the
streets and in emergency departments every week.
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This government has expressed its intention to ensure that the
health and security of UK citizens will not be negatively affected
by Brexit but has failed to provide any information on continued
collaboration with the EMCDDA. This presents substantial risks
to public health and safety. A solution will not be simple,
demanding urgent attention to tackle the legal and political
barriers to ensuring continued cooperation with the EMCDDA.
We call on the UK government to show leadership in taking all
necessary action to ensure continued collaboration with the
EMCDDA, thereby enabling health professionals to keep ahead
of the curve in a rapidly changing situation, allowing them to
continue participating in surveillance systems, to respond
appropriately to emerging threats, and to support policy and
operational responses. Ministers have committed to ensuring
that Brexit should not be allowed to undermine public health.
This is an opportunity to show that commitment.
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